Antidepressants and hair loss: understanding the link and your care options
Some antidepressants can be associated with hair loss. If shedding develops during treatment, tell your prescriber so that the medicine and other possible causes can be considered together. Do not change your medication without medical advice: its benefits for your mental health, your other prescriptions and an assessment of your scalp all matter when deciding what to do.
Useful starting points include when the shedding began, which areas are affected and what changed in the preceding months. At Body Expert, we distinguish this medical assessment from planning a hair transplant in Turkey, which may be considered for certain lasting forms of loss after diagnosis. Recent thinning while taking an antidepressant first needs an assessment of its possible causes.
How can antidepressants affect hair?
Each follicle moves through a period of hair production, a transitional stage and a resting stage before renewal. In telogen effluvium, more hairs than usual are shed after resting. The change generally affects the scalp diffusely and may first become noticeable when washing, brushing or detangling your hair.
Medicines are among the factors that can disturb this process. The precise explanation for antidepressant-associated shedding remains incompletely understood, however. Knowing how the hair growth cycle works helps explain why a change in treatment can precede the visible change in your hair by several weeks or longer.
Diffuse shedding alone cannot identify its trigger. A recent illness, substantial emotional stress, weight loss or another hair condition may coincide with the prescription. Your clinician will consider these events alongside the medicine to build a useful timeline, including changes that happened before the first tablet was taken or the shedding became obvious.
Which medicines have been linked to hair loss?
Published reports describe shedding during treatment with selective serotonin reuptake inhibitors, or SSRIs, including sertraline and fluoxetine. Alopecia also appears among the adverse effects in official product information for some sertraline preparations. Recognising a possible side effect helps inform the assessment, while an individual review is still needed to establish how likely the connection is.
Comparative research has examined other medicines, including venlafaxine, duloxetine and bupropion. Being included in such research does not mean that everyone taking a drug will lose hair or that the medicines suit the same people. Their licensed uses and availability also vary between countries, which matters when reading international treatment comparisons.
Make a note of the active ingredient, prescribed dose and dates of any changes before speaking to your GP or prescriber. Include medicines for other conditions and products bought without a prescription. Treatments sometimes used together in mental health care belong to different drug families, so a broad online list may combine medicines with quite different purposes and precautions.
What do comparisons between treatments actually show?
A 2018 study by Etminan and colleagues examined records from 1,025,140 new antidepressant users in the United States. Diagnosed alopecia was more likely with bupropion than fluoxetine, with a hazard ratio of 1.46. This is a relative comparison between groups; it does not mean that 46% of people taking bupropion lose their hair.
The same study reported a ratio of 0.99 for paroxetine compared with fluoxetine, with a confidence interval consistent with no difference. These observational findings cannot identify the best antidepressant for your hair. Prescribing also takes account of expected benefits, other adverse effects and previous treatment responses.
A separate review published in 2022 collected 71 patients described in 38 publications about SSRIs. These selected reports document possible associations, but cannot establish how frequently shedding occurs among everyone taking these medicines. Understanding the difference between a product leaflet, a case report and a comparative study helps make sense of apparently conflicting figures online.
When can shedding appear after starting treatment?
Telogen effluvium often becomes apparent a few months after a triggering event. Hairs that have already moved through the cycle may continue to shed after that event has passed. For this reason, an appointment usually considers the preceding weeks and months as well as what has happened immediately before you noticed the problem.
The review of published SSRI-associated cases found a median reported onset of 8.6 weeks, with considerable variation. That figure describes the selected reports and cannot predict when an individual will develop a side effect. Earlier or later shedding also deserves assessment; timing alone cannot confirm or rule out the medicine as a contributor.
Record the treatment start date, any prescribed changes and when you first noticed increased shedding as separate events. If you have already altered how you take the medicine without advice, explain exactly what happened. This information helps your prescriber interpret the changes and work with you on a suitable plan for continuing care.
What should you bring to an appointment?
Bring your prescription details and a list of everything else you take, including supplements. A short timeline and photographs taken under comparable conditions can help show the changes. Describe whether your main concern is extra hair on the brush, a general reduction in volume or clearly defined areas where hair has become sparse.
Your clinician will look at the pattern of loss and the condition of the scalp. The examination can help distinguish shedding from broken hairs and identify another condition that may need attention. Mention pain, redness, persistent itching or sores even if you already suspect that your antidepressant explains the problem.
Recent illnesses, dietary changes, changes in weight and family history also help guide the assessment. Blood tests may be appropriate when the findings suggest a deficiency or a hormonal problem. The relationship between thyroid problems and hair loss may be explored where relevant; the investigations should reflect your circumstances rather than a fixed checklist for every patient.
Explain how the concern affects daily life and your willingness to continue the prescription. If you are skipping doses or thinking about stopping because of your hair, tell the prescriber directly. This gives you an opportunity to discuss the impact, agree when to review progress and arrange dermatology input if the cause remains uncertain.
Should your antidepressant be changed?
Any decision about changing treatment belongs in a discussion with your prescriber. After assessing other explanations, they may suggest monitoring while you continue, treating an additional cause or considering an adjustment when a medicine-related effect seems likely. Improvements already achieved in your mental health are part of that decision.
The NHS advises that stopping suddenly can cause withdrawal symptoms. When stopping is appropriate, the reduction is planned individually and may take a variable amount of time. The medicine, length of treatment, previous experiences and symptoms during dose reduction can all affect the pace; a standard schedule from an online article cannot account for these factors.
Switching antidepressants also requires consideration of interactions and the transition between medicines. Ask what changes to watch for, when to contact the practice and when your hair should be reassessed. Improvement following a change provides further information, although its interpretation also depends on other treatments or health changes occurring during the same period.
Check before replacing the prescription with something advertised as natural. St John’s wort, for example, can interact with antidepressants. A pharmacist can help identify the ingredients in a supplement, check for relevant interactions and advise which questions need to be discussed with your prescriber before you start taking it.
What hair care can support recovery?
Management depends on the cause of the shedding and any abnormalities identified during assessment. A supplement may be appropriate for a recognised nutritional need, but a product sold for hair does not automatically address a medicine-related adverse effect. Mention dietary restrictions or reduced appetite so that advice can reflect what you are actually able to eat.
Everyday care can help reduce breakage and improve comfort through gradual detangling, looser styling and moderate heat. Choose cleansing products that your scalp tolerates. If irritation begins after introducing a new product, mention it at the review because an additional scalp problem can make the original changes harder to assess.
Minoxidil may be considered for some forms of alopecia after the diagnosis has been established. Its role in an acute telogen effluvium needs individual discussion, and using it does not replace a review of the suspected medicine. Avoid adding several hair-loss treatments together without knowing which problem each is intended to address or how progress will be assessed.
Changes in shedding and visible density can follow different timelines. Your clinician may suggest a review against the initial observations, allowing time to assess progress between treatment decisions. Keeping separate notes on the amount shed, scalp symptoms and the appearance of thinning areas can make that conversation more useful than repeatedly changing several products at once.
When does persistent hair loss need reassessment?
Hair loss that continues, spreads or changes its pattern needs another assessment. Patches, an inflamed scalp, pain or changes involving the eyebrows should be checked. New general symptoms, including unusual fatigue or unexplained weight changes, can also provide clues to other conditions that may need investigation alongside the medicine review.
More than one process can be present: a shedding episode may make previously subtle pattern thinning more noticeable. The return of visible volume depends on the conditions involved, even when fewer hairs are coming out during washing. A dermatologist can help identify which changes are temporary and which may need continuing management.
Prolonged shedding does not automatically mean that follicles have been destroyed. Distinguishing scarring from non-scarring loss requires examination, with further investigations where necessary. Our hair transplantation guide explains the assessment involved in a surgical plan, which cannot be based simply on how long the shedding has lasted.
Where does transplantation fit after assessment?
An ongoing medicine-related effluvium first needs attention to its cause and progress. Transplantation does not correct the factor disturbing the growth cycle. A separate, lasting form of loss may eventually be assessed for a procedure once its underlying cause and stability are sufficiently clear, alongside the condition of the existing hair.
If you already have plans for surgery, share your complete prescription list with the team providing care. The considerations around hair transplants and antidepressants relate to that particular stage and require coordination between the relevant clinicians. A proposed cosmetic procedure is another reason to keep your prescriber informed about any advice concerning your medication.
At Body Expert, a discussion about a hair transplant in Istanbul should take account of the diagnosis and your ongoing medical care. Bring relevant reports and a record of the changes so that your situation can be assessed. Protecting the benefits of your mental health treatment remains part of addressing the hair loss that concerns you.
Sources
Agence nationale de sécurité du médicament et des produits de santé. (2022, July 12). SERTRALINE ALTER 50 mg, gélule: Summary of product characteristics. French public medicines database.
Etminan, M., Sodhi, M., Procyshyn, R. M., Guo, M., & Carleton, B. C. (2018). Risk of hair loss with different antidepressants: A comparative retrospective cohort study. International Clinical Psychopharmacology, 33(1), 44-48. https://doi.org/10.1097/YIC.0000000000000191.
Malkud, S. (2015). Telogen effluvium: A review. Journal of Clinical and Diagnostic Research, 9(9), WE01-WE03. https://doi.org/10.7860/JCDR/2015/15219.6492.
MedlinePlus. (2025, June 3). Hair loss. National Library of Medicine. https://medlineplus.gov/ency/article/003246.htm.
National Health Service. (2025, June 12). Antidepressants. Retrieved November 7, 2026. https://www.nhs.uk/medicines/antidepressants/.
Pejcic, A. V., & Paudel, V. (2022). Alopecia associated with the use of selective serotonin reuptake inhibitors: Systematic review. Psychiatry Research, 313, 114620. https://doi.org/10.1016/j.psychres.2022.114620.